Twist Bioscience, a US-based biotechnology company focused on synthesising DNA, has closed a $37m series C round led by biotechnology company Illumina and featuring diversified financial conglomerate Fidelity Management and Research.
Foresite Capital Management, and existing investors Tao Invest, Arch Venture Partners, Paladin Capital Group, Yuri Milner as well as a range of unnamed corporate and venture investors also contributed to the funding round.
Founded in 2013, Twist has developed a platform to create synthetic DNA. DNA, or deoxyribonucleic acid,…
